Related references
Note: Only part of the references are listed.Nature does things well
[Anonymous]
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter W. Horby et al.
LANCET (2022)
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial
E. Wesley Ely et al.
LANCET RESPIRATORY MEDICINE (2022)
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Genetic mechanisms of critical illness in COVID-19
Erola Pairo-Castineira et al.
NATURE (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
P. W. Horby et al.
LANCET (2021)
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani et al.
LANCET (2021)
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Peter W. Horby et al.
LANCET (2021)
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis
Manu Shankar-Hari et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
Patricia O. Guimaraes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo- controlled phase 3 trial
Vincent C. Marconi et al.
LANCET RESPIRATORY MEDICINE (2021)
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Group Author Only
LANCET RESPIRATORY MEDICINE (2021)
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Peter Richardson et al.
LANCET (2020)
Mechanism of baricitinib supports artificial intelligence-predicted testing inCOVID-19 patients
Justin Stebbing et al.
EMBO MOLECULAR MEDICINE (2020)
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Yang Cao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter W. Horby et al.
LANCET (2020)
An inflammatory cytokine signature predicts COVID-19 severity and survival
Diane Marie Del Valle et al.
NATURE MEDICINE (2020)
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Peter Horby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials
Jonathan A. C. Sterne et al.
TRIALS (2020)
JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Shubhasree Banerjee et al.
DRUGS (2017)